STOCK TITAN
  1. Home
  2. Sec-filings
  3. OFIX
  4. [Form 4] Orthofix Medical Inc. Insider Trading Activity

OFIX Director Kummeth’s Equity Grant Boosts Stake by 46%

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Orthofix Medical (OFIX) filed a Form 4 disclosing that director Charles R. Kummeth was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost. The DSUs vest in full on the first anniversary of the grant date and will convert into common stock within 45 days after his service with the company ends. Following the award, Kummeth’s total beneficial ownership rose to 59,237 shares, which now includes 23,502 previously reported DSUs and 1,894 shares accumulated through Orthofix’s Stock Purchase Plan.

Positive

  • Material ownership increase: Director Charles R. Kummeth received 18,841 deferred stock units (~46 % addition), lifting his stake to 59,237 shares.

Negative

  • None.

Insights

TL;DR: Director granted 18,841 DSUs—material size but compensation-driven; neutral market signal.

The transaction adds roughly 46 % to Charles Kummeth’s prior stake, surpassing materiality thresholds for insider filings. Because the award is service-based and settled post-tenure, it does not represent immediate cash buying or selling pressure. The filing lacks price data, open-market activity, or derivative exercises, suggesting a neutral impact for near-term trading sentiment while modestly strengthening long-term alignment.

Insider Kummeth Charles R.
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 18,841 $0.00 --
Holdings After Transaction: Common Stock — 59,237 shares (Direct)
Footnotes (1)
  1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Includes 23,502 previously reported deferred stock units and an aggregate of 1,894 shares acquired under Orthofix's Stock Purchase Plan on 10/31/2024 and 4/30/2025..
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kummeth Charles R.
(Last) (First) (Middle)
3451 PLANO PARKWAY
(Street)
LEWISVILLE TX 75056
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 18,841(1) A $0 59,237(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
2. Includes 23,502 previously reported deferred stock units and an aggregate of 1,894 shares acquired under Orthofix's Stock Purchase Plan on 10/31/2024 and 4/30/2025..
/s/ Geoffrey Gillespie, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many shares did Orthofix (OFIX) director Charles R. Kummeth acquire on 06/18/2025?

The Form 4 reports an award of 18,841 deferred stock units.

What is Charles R. Kummeth’s total beneficial ownership in OFIX after the transaction?

His holdings increased to 59,237 shares of Orthofix common stock.

When do the newly granted deferred stock units vest?

The DSUs vest in full on the first anniversary of the 06/18/2025 grant date, subject to continued service.

Are the shares from this Form 4 an open-market purchase?

No. They are service-based deferred stock units granted at no cash cost.

What other shares are included in Kummeth’s ownership total?

The total includes 23,502 previously reported DSUs and 1,894 shares bought through the company’s Stock Purchase Plan.